(Photo Courtesy: www.webmd.com)
NOACs have seen substantial uptake since the launch of Pradaxa in 2010, with the drugs accounting for approximately 70% of all AF therapeutics sales in 2013.
Dr Haylyn Wong, GlobalData's senior analyst covering cardiovascular & metabolic disorders, said that, the increased adoption of NOACs will be the primary driver of market growth across the eight major markets, comprising of the US, France, Germany, Italy, Spain, UK, Japan, and Canada, over the forecast period.
Dr Wong explained: "Prior to the approval of the first NOACs, namely Pradaxa, Xarelto and Eliquis, the anticoagulant market for the prevention of stroke in AF patients was dominated by generic vitamin K antagonists, particularly warfarin.
"However, GlobalData expects that the advances offered by NOACs in terms of improved safety and the lack of a need for routine monitoring will see these treatments taking market share away from warfarin."
The analyst remarked that the AF therapeutics market will also be driven by the recent launch of a fourth NOAC, Daiichi-Sankyo's Savaysa, which will provide an additional anticoagulant treatment option for AF patients.